Birmingham, AL3 Active Studies

Hereditary Angioedema Clinical Trials in Birmingham, AL

Find 3 actively recruiting hereditary angioedema clinical trials in Birmingham, AL. Connect with local research sites and explore new treatment options.

3
Active Trials
3
Sponsors
313
Enrolling

Recruiting Hereditary Angioedema Studies in Birmingham

About Hereditary Angioedema Clinical Trials in Birmingham

Hereditary angioedema (HAE) is a rare genetic condition causing recurrent episodes of severe swelling in various body parts. It is caused by deficiency or dysfunction of C1 inhibitor protein. Treatment includes on-demand therapy for attacks and prophylactic medications to prevent episodes.

There are currently 3 hereditary angioedema clinical trials recruiting participants in Birmingham, AL. These studies are seeking a combined 313 participants. Research is being sponsored by Astria Therapeutics, Inc., Pharvaris Netherlands B.V., KalVista Pharmaceuticals, Ltd.. Clinical trial participation is free and participants receive study-related medical care at no cost.

Hereditary Angioedema Clinical Trials in Birmingham — FAQ

Are there hereditary angioedema clinical trials in Birmingham?

Yes, there are 3 hereditary angioedema clinical trials currently recruiting in Birmingham, AL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Birmingham?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Birmingham research site will contact you about next steps.

Are clinical trials in Birmingham free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Birmingham studies also compensate for your time and travel.

What hereditary angioedema treatments are being tested?

The 3 active trials in Birmingham are testing new therapies including novel drugs, biologics, and treatment approaches for hereditary angioedema.

Data updated March 2, 2026 from ClinicalTrials.gov